Targeting of the β6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.

Oncol Rep · 2014 · PMC4203328 · PMID 25176506

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

More recent evidence suggests that αvβ6 may be used to identify patients who have a highly significant increased risk of developing metastatic disease and may serve for risk stratification of patients with breast ductal carcinoma in situ (DCIS) ( 14 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.